Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Do the results raise any concerns about the company's ability to meet its long‑term strategic objectives or affect its risk profile? How did Tourmaline Bio's Q2 2025 revenue and earnings compare to consensus estimates? What were the key drivers behind any revenue or earnings beat/miss in this quarter? Did the company provide any guidance or outlook for Q3 2025 or the full year, and how does that affect our valuation models? Are there any notable changes in the company's cash balance, capital expenditures, or financing activities that could impact liquidity? How does Tourmaline Bio's performance this quarter compare to its direct competitors in the biotech sector? Did the earnings release include any updates on the progress of clinical trials or pipeline developments that could affect future revenue streams? Are there any upcoming catalysts (e.g., data readouts, FDA decisions, conference presentations) that could drive the stock price in the near term? What specific business highlights (e.g., new partnerships, product milestones, regulatory updates) were announced, and how might they influence future growth? What is the market's reaction to the earnings release so far, and does the current trading volume suggest a sustained move?